Much evidence indicates that the memory and cognitive deficits of patients with Alzheimer's disease are closely associated with dysfunction of central cholinergic system. The degree of reduction of choline acetyltransferase activity in cerebral cholinergic neurons is significantly correlated with the severity of dementia or cognitive impairments observed in Alzheimer's disease. Therefore, Alzheimer's disease may be slowed by supplementation of exogenous choline acetyltransferase. Here we show that choline acetyltransferase mediated by TAT protein transduction domain passes through the blood-brain barrier and enters the neurons in mice, increasing choline acetyltransferase and neurotransmitter acetylcholine contents. The recombination TAT-choline acetyltransferase fusion protein injected intravenously improves the memory and cognitive dysfunction in Alzheimer's disease model mice induced by amyloid-beta peptide. Our results imply a novel and potentially effective way for Alzheimer's disease therapy. 相似文献
Summary: Novel temperature sensitive poly(N‐isopropylacrylamide‐co‐acryloyl beta‐cyclodextrin) (P(NIPA‐co‐A‐CD)) hydrogels with fast shrinking rates were prepared by radical polymerization of NIPA, A‐CD and crosslinker in a mixture of water/1,4‐dioxane as solvent. Because the mixed solvent was a poor solvent for the copolymers, phase separation occurred during the polymerization, which resulted in a heterogeneous, porous structure of the hydrogels. In contrast to the normal PNIPA hydrogel and the homo P(NIPA‐co‐A‐CD) gel prepared in water, the P(NIPA‐co‐A‐CD) hydrogels synthesized in water/1,4‐dioxane as solvent exhibited higher swelling ratios at the temperature below the lower critical solution temperature (LCST) and shrunk rapidly to equilibrium within shorter time when the temperature was increased above LCST. Increasing the acryloyl beta‐cyclodextrin content in the gels led to a slight decrease of the swelling ratio at lower temperature and had no marked influence on the shrinking kinetics. The gels prepared in water/1,4‐dioxane, at different v/v ratios of 1.0/0.2, 0.8/0.4 and 0.6/0.6, showed similar properties.
SEM photos of the heterogeneous P(NIPA‐co‐A‐CD) hydrogel prepared in water/1,4‐dioxane. 相似文献
A new SARS animal model was established by inoculating SARS coronavirus (SARS-CoV) into rhesus macaques (Macaca mulatta) through the nasal cavity. Pathological pulmonary changes were successively detected on days 5-60 after virus inoculation. All eight animals showed a transient fever 2-3 days after inoculation. Immunological, molecular biological, and pathological studies support the establishment of this SARS animal model. Firstly, SARS-CoV-specific IgGs were detected in the sera of macaques from 11 to 60 days after inoculation. Secondly, SARS-CoV RNA could be detected in pharyngeal swab samples using nested RT-PCR in all infected animals from 5 days after virus inoculation. Finally, histopathological changes of interstitial pneumonia were found in the lungs during the 60 days after viral inoculation: these changes were less marked at later time points, indicating that an active healing process together with resolution of an acute inflammatory response was taking place in these animals. This animal model should provide insight into the mechanisms of SARS-CoV-related pulmonary disease and greatly facilitate the development of vaccines and therapeutics against SARS. 相似文献
Crescentic glomerulonephritis (GN) demonstrates immunopathological features of a T helper (Th)1-directed delayed-type hypersensitivity (DTH) response. The capacity of Th2 cytokines to attenuate crescentic glomerular injury in this disease was examined by administering interleukin (IL)-4 and IL-10, singly and in combination. GN was induced by i.v. administration of sheep anti-mouse glomerular basement membrane (GBM) globulin to mice sensitized to sheep globulin 10 days earlier. Treatment (2.5 μg, i.p.) with IL-4, IL-10, or both IL-4 and IL-10 (IL-4+10), was started 1 h before sensitization and continued daily until the end of the study (10 days after administration of anti-GBM globulin). Control mice treated with PBS developed GN with glomerular accumulation of T cells and macrophages, crescents in 42.5 ± 4.5 % of glomeruli (normal 0 %), proteinuria (8.3 ± 0.9 mg/24 h, normal 0.74 ± 0.08 mg/24 h, p < 0.001) and renal impairment (creatinine clearance [cr/cl]: 93 ± 12 μ1/min, normal 193 ± 10 μ1/min, p<0.001). 1reatment with either IL-4, IL-10, or IL-4+10 prevented crescent formation (crescentic glomeruli: 0.8 ± 0.5, 1.2 ± 0.9, and 1.4 ± 1.0 %, respectively, all p<0.01 compared to control) and attenuated proteinuria (3.6 ± 1.0, 2.2 ± 0.5, and 2.9 ± 0.5 mg/24 h, respectively, all p<0.01 compared to control). IL-4+10 prevented development of renal impairment (cr/cl: 183 ± 22 μ1/min); IL-10 given alone limited the decline in renal function (cr/cl: 150 ± 20 μ1/min), but IL-4 alone did not provide any significant protection (cr/cl: 121 ± 17 μ1/min). All treatments markedly diminished glomerular T cell and macrophage accumulation, reduced interferon-γ production by splenic T cells, prevented cutaneous DTH to the disease-initiating antigen and reduced antigen-specific immunoglobulin of the IgG2a and IgG3 isotypes. These data demonstrate that crescentic GN and renal impairment can be prevented by administration of Th2 cytokines and that this effect is associated with attenuation of the Th1 response to the disease-initiating antigen. 相似文献